ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (ARISE2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03542851
Recruitment Status : Recruiting
First Posted : May 31, 2018
Last Update Posted : June 6, 2018
Sponsor:
Information provided by (Responsible Party):
Balance Therapeutics

Brief Summary:
This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.

Condition or disease Intervention/treatment Phase
Idiopathic Hypersomnia Drug: Pentetrazol (PTZ) Drug: Placebo oral capsule Phase 2

Detailed Description:
This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia (IH). The objectives of this study are two-fold: 1) To evaluate the efficacy of BTD-001 in subjects with IH as reflected by changes in cognitive, sleep, functional, and quality-of-life measures and 2) To characterize the safety and tolerability of oral BTD-001 administered to subjects with IH.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia
Actual Study Start Date : May 29, 2018
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Subject Receives BTD001 first Drug: Pentetrazol (PTZ)
BTD-001 is an oral capsule of PTZ.
Other Name: PTZ

Drug: Placebo oral capsule
Placebo will be presented as oral capsule.

Experimental: Subject Receives Placebo first Drug: Pentetrazol (PTZ)
BTD-001 is an oral capsule of PTZ.
Other Name: PTZ

Drug: Placebo oral capsule
Placebo will be presented as oral capsule.




Primary Outcome Measures :
  1. The efficacy of BTD-001 in subjects with IH as reflected by the IH Symptom Diary [ Time Frame: Change from baseline. ]
    Measurements: IH Symptom Diary.


Secondary Outcome Measures :
  1. The efficacy of BTD-001 in subjects with IH as reflected by changes in functional measures. [ Time Frame: Change from baseline. ]
    Measurements: ESS (Epworth Sleepiness Scale).

  2. The efficacy of BTD-001 in subjects with IH as reflected by changes in sleep measures. [ Time Frame: Change from baseline. ]
    Measurements: MWT (Maintenance of Wakefulness Test)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or Females age 18 to 55 years old
  • Onset of hypersomnia between age 10 and 30 years of age
  • An Epworth Sleepiness Scale score of greater than or equal to 11
  • Able to comply with requirements for concomitant medications and consumption of caffeine, alcohol, tobacco and nicotine
  • Females with a negative pregnancy test AND who are non-lactating
  • Sexually active females of childbearing potential must be willing to use a highly effective method of birth control
  • Sexually active males must have a vasectomy or use condoms

Exclusion Criteria:

  • History of any disorder causing hypersomnia other than IH
  • Evidence of circadian-rhythm disorder
  • Sleep apnea syndrome
  • Use of CPAP
  • Obese subjects with BMI greater than or equal to 35kg/m2
  • History of or current significant pulmonary, cardiac, neurological or psychiatric disease
  • Columbia-Suicide Severity Rating Scale (C-SSRS) findings consistent with significant history of or current suicidal ideation or behavior
  • Subjects who fail to wash out medications for IH or any other prohibited medications
  • Positive toxicology screen test during the Screening or Baseline Visits.
  • Clinically significant abnormal findings from physical, electrocardiogram (ECG) or laboratory assessments at Screening
  • History of or current significant pulmonary, cardiac, neurological or psychiatric disease, substance dependence, porphyria, malignancy or hypothyroidism (unless euthyroid at Screening Visit and treated with a stable dose of medication for at least 3 months prior to the Baseline Visit).
  • Participation in a clinical drug trial within 4 weeks of Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03542851


Contacts
Contact: Nichole Baio 650-351-7677 nichole.baio@balance-therapeutics.com

Locations
United States, Colorado
Research Site Recruiting
Boulder, Colorado, United States, 80301
Contact    303-443-7229 ext 105      
United States, Georgia
Research SIte Not yet recruiting
Atlanta, Georgia, United States, 30342
Contact    404-851-9934      
United States, Kentucky
Research Site Recruiting
Louisville, Kentucky, United States, 40218
Contact    502-479-1217      
Sponsors and Collaborators
Balance Therapeutics
Investigators
Study Director: Morgan Lam Chief Operating Officer

Responsible Party: Balance Therapeutics
ClinicalTrials.gov Identifier: NCT03542851     History of Changes
Other Study ID Numbers: BTD-001 IH202
First Posted: May 31, 2018    Key Record Dates
Last Update Posted: June 6, 2018
Last Verified: June 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Disorders of Excessive Somnolence
Hypersomnolence, Idiopathic
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders